At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALMS Alumis Inc.
Pre-Mkt 10-26 08:04:40 EDT
6.78
-0.04
-0.59%
盘前6.95
+0.17+2.51%
07:39 EDT
High6.83Low6.48Vol1.23M
Open6.68D1 Closing6.82Amplitude5.05%
Mkt Cap874.62MTradable Cap619.31MTotal Shares129.00M
T/O8.27MT/O Rate1.35%Tradable Shares91.34M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data
Reuters  ·  10-09
Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data
Alumis Says Phase 3 Data Show Envudeucitinib Delivers 54% PASI 100 Response at Week 48 in Psoriasis Trial
Reuters  ·  10-09
Alumis Says Phase 3 Data Show Envudeucitinib Delivers 54% PASI 100 Response at Week 48 in Psoriasis Trial
Alumis - over 80% of Onward3 Patients Maintain Clear or Almost Clear Scalp Skin at 48 Weeks
THOMSON REUTERS  ·  10-09
Alumis - over 80% of Onward3 Patients Maintain Clear or Almost Clear Scalp Skin at 48 Weeks
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
THOMSON REUTERS  ·  10-09
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
Alumis - Plans Nda Submission for Envudeucitinib in 4Q 2026
THOMSON REUTERS  ·  10-09
Alumis - Plans Nda Submission for Envudeucitinib in 4Q 2026
Alumis - Onward3 Shows 54% Pasi 100 Skin Clearance at Week 48 for Envudeucitinib
THOMSON REUTERS  ·  10-09
Alumis - Onward3 Shows 54% Pasi 100 Skin Clearance at Week 48 for Envudeucitinib
Alumis Initiated With Buy on TYK2 Opportunity; Envu’s Strong Psoriasis Profile Supports Unchanged $15 Price Target
TIPRANKS  ·  10-05
Alumis Initiated With Buy on TYK2 Opportunity; Envu’s Strong Psoriasis Profile Supports Unchanged $15 Price Target
Top Premarket Gainers
MT Newswires Live  ·  09-10
Top Premarket Gainers
Alumis Director Srinivas Akkaraju Reports Disposal of 96,131 Common Shares Worth $1.01 Million
Reuters  ·  09-10
Alumis Director Srinivas Akkaraju Reports Disposal of 96,131 Common Shares Worth $1.01 Million
Wells Fargo Sticks to Its Buy Rating for Alumis Inc. (ALMS)
TIPRANKS  ·  09-10
Wells Fargo Sticks to Its Buy Rating for Alumis Inc. (ALMS)
Alumis to Present at Wells Fargo Annual Healthcare Investor Conference
Reuters  ·  09-04
Alumis to Present at Wells Fargo Annual Healthcare Investor Conference
Analysts’ Top Healthcare Picks: uniQure (QURE), Alumis Inc. (ALMS)
TIPRANKS  ·  09-03
Analysts’ Top Healthcare Picks: uniQure (QURE), Alumis Inc. (ALMS)
Alumis Cut to Neutral from Buy by Guggenheim
Dow Jones  ·  09-03
Alumis Cut to Neutral from Buy by Guggenheim
Guggenheim Downgrades Alumis to Neutral From Buy
MT Newswires Live  ·  09-03
Guggenheim Downgrades Alumis to Neutral From Buy
Alumis downgraded to Neutral from Buy at Guggenheim
TIPRANKS  ·  09-03
Alumis downgraded to Neutral from Buy at Guggenheim
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Alumis Inc. (ALMS)
TIPRANKS  ·  09-03
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Alumis Inc. (ALMS)
Top Midday Gainers
MT Newswires Live  ·  09-03
Top Midday Gainers
Alumis rises 10.7%
TIPRANKS  ·  09-03
Alumis rises 10.7%
Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says
MT Newswires Live  ·  09-02
Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says
Alumis Price Target Cut to $15.00/Share from $25.00 by HC Wainwright & Co.
Dow Jones  ·  09-02
Alumis Price Target Cut to $15.00/Share from $25.00 by HC Wainwright & Co.

Introduction

Company Name.
Alumis Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Alumis Inc. was incorporated on January 29, 2021, as a Delaware corporation. It is a clinical-stage biopharmaceutical company initially focused on developing two tyrosine kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor designed to achieve maximal target inhibition, and A-005, a CNS-penetrant molecule. The company's mission is to significantly improve patients' lives by replacing broad immunosuppression with targeted therapies.
Issue price:
--